Inclisiran

GPTKB entity

Statements (67)
Predicate Object
gptkbp:instanceOf gptkb:drug
small interfering RNA
gptkbp:approvalYear 2020
gptkbp:approvedBy gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
gptkbp:ATCCode C10AX16
gptkbp:brand gptkb:Leqvio
gptkbp:CASNumber 1639324-58-2
gptkbp:chemicalFormula C529H642F10N176O316P43S6
gptkbp:developer gptkb:Alnylam_Pharmaceuticals
gptkb:Novartis
gptkbp:eliminationHalfLife 9-13 days
https://www.w3.org/2000/01/rdf-schema#label Inclisiran
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction PCSK9 inhibitor
gptkbp:pregnancyCategory Not assigned (US)
gptkbp:reduces gptkb:LDL_cholesterol
gptkbp:routeOfAdministration subcutaneous injection
gptkbp:sideEffect bronchitis
nausea
diarrhea
dizziness
fatigue
headache
hypertension
urinary tract infection
back pain
cough
injection site reaction
rash
elevated liver enzymes
injection site pain
hypersensitivity
dyspnea
arthralgia
myalgia
nasopharyngitis
pain in extremity
musculoskeletal pain
increased creatine kinase
injection site abscess
injection site atrophy
injection site bruising
injection site cellulitis
injection site discomfort
injection site erythema
injection site hematoma
injection site hyperpigmentation
injection site hypopigmentation
injection site induration
injection site infection
injection site mass
injection site necrosis
injection site nodule
injection site pruritus
injection site rash
injection site scab
injection site scar
injection site swelling
injection site ulcer
injection site warmth
gptkbp:target gptkb:PCSK9_mRNA
gptkbp:UNII 6Z1Y2V4S2E
gptkbp:usedFor gptkb:familial_hypercholesterolemia
atherosclerotic cardiovascular disease
gptkbp:bfsParent gptkb:NOVN
gptkbp:bfsLayer 5